A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
Zhang, Tian-Ying; Guo, Xue-Ran; Wu, Yang-Tao; Kang, Xiao-Zhen; Zheng, Qing-Bing; Qi, Ruo-Yao; Chen, Bin-Bing; Lan, Ying; Wei, Min; Wang, Shao-Juan; Xiong, Hua-Long; Cao, Jia-Li; Zhang, Bao-Hui; Qiao, Xiao-Yang; Huang, Xiao-Fen; Wang, Ying-Bin; Fang, Mu-Jin; Zhang, Ya-Li; Cheng, Tong; Chen, Yi-Xin; Zhao, Qin-Jian; Li, Shao-Wei; Ge, Sheng-Xiang; Chen, Pei-Jer; Zhang, Jun; Yuan, Quan; Xia, Ning-Shao.
; 2019 Mar 29.
Artigo em Inglês | MEDLINE | ID: mdl-30926653
Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.
Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.
Booster dose vaccination for preventing hepatitis B.
Unimpaired immunogenicity of yeast-expressed hepatitis B surface antigen stored at elevated temperatures.